Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Global cancer supportive care drugs market 360° synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Drug class trends
2.1.4 Cancer type trends
2.1.5 Distribution channel trends
Chapter 3 Cancer Supportive Care Drugs Market Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence and prevalence of cancer
3.2.1.2 Increasing technological advancements in cancer therapies
3.2.1.3 Rising geriatric population
3.2.1.4 Growing integration of digital health
3.2.1.5 Increasing awareness among patients and healthcare professionals about the availability and benefits of supportive care drugs
3.2.2 Industry pitfalls & challenges
3.2.2.1 Availability of alternative therapies or complementary treatments
3.2.2.2 Limited healthcare resources
3.2.2.3 Adverse effect drugs
3.3 Growth potential analysis
3.3.1 By drug class
3.3.2 By cancer type
3.3.3 By distribution channel
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company positioning matrix, 2022
4.4 Competitive analysis of major market players, 2022
4.5 Strategy dashboard, 2022
Chapter 5 Cancer Supportive Care Drugs Market Size and Forecast, By Drug class (USD Million)
5.1 Key trends, by drug class
5.2 G-CSFs (Granulocyte-colony Stimulating Factors)
5.3 ESAs (Erythropoiesis Stimulating Agents)
5.4 Anti-emetics
5.5 Bisphosphonates
5.6 Opioids
5.7 NSAIDs
5.8 Other drugs
Chapter 6 Cancer Supportive Care Drugs Market Size and Forecast, By Cancer type (USD Million)
6.1 Key trends, by cancer type
6.2 Breast cancer
6.3 Lung cancer
6.4 Melanoma
6.5 Prostate cancer
6.6 Colorectal cancer
6.7 Liver cancer
6.8 Stomach cancer
6.9 Other cancer types
Chapter 7 Cancer Supportive Care Drugs Market Size and Forecast, By Distribution channel (USD Million)
7.1 Key trends, by distribution channel
7.2 Hospital pharmacies
7.3 Drug stores and retail pharmacies
7.4 Online pharmacies
Chapter 8 Cancer Supportive Care Drugs Market Size and Forecast, By Region (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East & Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 Amgen, Inc.
9.2 Merck & Co., Inc.
9.3 Johnson & Johnson Services, Inc.
9.4 Heron Therapeutics, Inc.
9.5 Novartis AG
9.6 GSK plc
9.7 F. Hoffmann-La Roche Ltd.
9.8 Helsinn Healthcare SA
9.9 Teva Pharmaceuticals Industries Ltd.
9.10 Fagron Group
